Company Ultimovacs ASA

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-06-20 EDT			5-day change	1st Jan Change
7.8 ^NOK	-4.99%		-6.25%	-93.65%

06-11	Ultimovacs Asa Provides Update from Phase I Study in Malignant Melanoma	CI
05-07	Transcript : Ultimovacs ASA, Q1 2024 Earnings Call, May 07, 2024

Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacsâ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.

Number of employees: 25

Managers	Title	Age	Since
Carlos de Sousa CEO	Chief Executive Officer	66	20-05-31
Hans Vassgård Eid DFI	Director of Finance/CFO	57	-
Ingunn Hagen Westgaard CTO	Chief Tech/Sci/R&D Officer	-	-
Jens Bjørheim CTO	Chief Tech/Sci/R&D Officer	-	-
Gustav Gaudernack CTO	Chief Tech/Sci/R&D Officer	-	-
Øivind Foss CTO	Chief Tech/Sci/R&D Officer	-	-
Audun Tornes CTO	Chief Tech/Sci/R&D Officer	-	-
Anne Hovi Worsøe IRC	Investor Relations Contact	60	21-09-30
Mc Callion Orla LAW	General Counsel	-	21-09-30
Gudrun Trøite PRN	Corporate Officer/Principal	-	-

Members of the board	Title	Age	Since
Jónas Einarsson CHM	Chairman	67	11-01-25
Henrik Schüssler BRD	Director/Board Member	61	14-12-31
Kari Grønås BRD	Director/Board Member	59	18-12-31
Haakon Stenrod BRD	Director/Board Member	44	20-11-10

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	34,406,061	23,368,039 ( 67.92 %)	0	67.92 %

Name	Equities	%	Valuation
Bjørn Rune Gjelsten 18.89 %	6,495,866	18.89 %	6 M kr
Wilhelmsen Family 5.177 %	1,780,575	5.177 %	2 M kr
Hagen Stein Erik Family 4.960 %	1,705,957	4.960 %	1 M kr
Radiumhospitalets Forskningsstiftelse 4.417 %	1,519,263	4.417 %	1 M kr
Langøya Invest AS 4.059 %	1,396,006	4.059 %	1 M kr
Inven2 AS 3.989 %	1,372,163	3.989 %	1 M kr
Else Helene Sundt 2.808 %	965,802	2.808 %	827 712 kr
Christian Gruner Sundt 2.565 %	882,132	2.565 %	756 005 kr
Sundt AS 2.335 %	803,321	2.335 %	688 462 kr
Nordea Investment Management AB (Norway) 2.056 %	707,178	2.056 %	606 066 kr

Ultimovacs ASA

Ullernchausséen 64

0379, Oslo

+47 41 38 00 80

http://www.ultimovacs.com

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

7.8 NOK

Average target price

6.5 NOK

Spread / Average Target

-16.67%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ULTIMOVACS ASA	-93.65%	25.46M
MODERNA, INC.	+35.14%	51.51B
IQVIA HOLDINGS INC.	-7.43%	39.03B
LONZA GROUP AG	+35.88%	38.91B
CELLTRION, INC.	-10.62%	26.68B
ICON PUBLIC LIMITED COMPANY	+11.63%	26.13B
ALNYLAM PHARMACEUTICALS, INC.	-17.77%	19.91B
UNITED THERAPEUTICS CORPORATION	+40.52%	13.71B
MEDPACE HOLDINGS, INC.	+30.70%	12.38B
BIO-TECHNE CORPORATION	-3.41%	11.74B

Other Biotechnology & Medical Research